Tango Therapeutics Inc (TNGX) Stock Price, Quote & News

Company Profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repress...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 320 4900

Website: www.tangotx.com

Address:

201 Brookline Avenue, Suite 901, Boston, United States

erevnon Feb. 23 at 7:17 PM

Mizuho initiates coverage on Tango Therapeutics $TNGX at Outperform rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JesusIsKing1 Feb. 23 at 4:39 PM

$TNGX Added. Like the look of this one. Plenty of recent institutional buying, strong financials and looks strong.

0 · Reply

_EmproX Feb. 23 at 4:19 PM

$AUST $PNBK $TNGX $ODYS •<•

0 · Reply

notreload_ai Feb. 23 at 3:52 PM

Mizuho starts coverage on $TNGX with an Outperform rating and $19 price target, highlighting strong potential for lead drug vopimetostat in tough cancers like pancreatic and lung. https://notreload.xyz/mizuho-initiates-tngx-outperform/

0 · Reply

notreload_ai Feb. 23 at 3:09 PM

$AMPX $BOBS $LIFE $TNGX -- THE WSJ

0 · Reply

wheatbreadmetropolis Feb. 22 at 9:30 PM

$TNGX #1 trending.

0 · Reply

JesusIsKing1 Feb. 22 at 8:38 PM

$NOK Buying this and $TNGX tomorrow. Money to be made with this great companies in their infancy.

0 · Reply

JesusIsKing1 Feb. 22 at 8:37 PM

$TNGX Adding this one to my portfolio tomorrow along with $NOK.

0 · Reply

OfficialStocktwitsUser Feb. 16 at 8:28 PM

$TNGX RSI: 63.74, MACD: 0.5758 Vol: 0.52, MA20: 12.26, MA50: 10.65 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

BillionerOfKing Feb. 16 at 1:05 PM

$TNGX Current Stock Price: $12.90 Contracts to trade: $12.5 TNGX Feb 20 2026 Call Entry: $0.35 Exit: $0.64 ROI: 82% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 9:05 AM EST - 6 weeks ago

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Jan 5, 2026, 7:00 AM EST - 7 weeks ago

Tango Therapeutics Appoints Sung Lee to Board of Directors

Dec 17, 2025, 7:00 AM EST - 2 months ago

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 3 months ago

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 21, 2025, 4:20 PM EST - 3 months ago

Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy

Oct 23, 2025, 5:07 PM EDT - 4 months ago

Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript

Oct 23, 2025, 11:17 AM EDT - 4 months ago

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Oct 23, 2025, 7:20 AM EDT - 4 months ago

Tango Therapeutics Announces $225 Million Financing

Oct 6, 2025, 7:00 AM EDT - 5 months ago

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

Aug 26, 2025, 7:00 AM EDT - 6 months ago

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Aug 5, 2025, 7:00 AM EDT - 7 months ago

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Jun 27, 2025, 7:00 AM EDT - 8 months ago

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

May 27, 2025, 7:00 AM EDT - 9 months ago

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 9 months ago

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

May 12, 2025, 7:00 AM EDT - 10 months ago

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 1, 2025, 7:00 AM EDT - 10 months ago

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Mar 25, 2025, 4:30 PM EDT - 11 months ago

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Feb 27, 2025, 7:00 AM EST - 1 year ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

Jan 30, 2025, 7:00 AM EST - 1 year ago

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

Jan 23, 2025, 5:44 AM EST - 1 year ago

Tango Therapeutics: Chance For A Short Squeeze

Dec 3, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 27, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 7:05 AM EST - 1 year ago

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 6, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Sep 10, 2024, 12:45 PM EDT - 1 year ago

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics to Participate in Upcoming Investor Conferences

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 23, 2024, 9:18 AM EDT - 1 year ago

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

May 23, 2024, 7:19 AM EDT - 1 year ago

Tango Therapeutics to stop development of cancer therapy

May 23, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Announces Discontinuation of TNG348 Program

May 8, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Mar 5, 2024, 4:47 PM EST - 2 years ago

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

Jan 31, 2024, 7:00 AM EST - 2 years ago

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 25, 2024, 12:46 PM EST - 2 years ago

Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs

Jan 4, 2024, 2:47 AM EST - 2 years ago

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Nov 13, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

Nov 8, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Nov 7, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

Oct 23, 2023, 6:26 PM EDT - 2 years ago

Circling Bank On Tango Therapeutics

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

Aug 29, 2023, 5:08 PM EDT - 2 years ago

Tango Therapeutics Announces Updates to Its Board of Directors

Aug 10, 2023, 7:30 AM EDT - 2 years ago

Tango Stock Surges On Peer Data Merits Excitement And Perspective

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces $80 million Private Placement Financing

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Jul 26, 2023, 7:29 PM EDT - 2 years ago

Tango Therapeutics: Partial Phase 1 Data Has Not Helped

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

Jul 10, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

erevnon Feb. 23 at 7:17 PM

Mizuho initiates coverage on Tango Therapeutics $TNGX at Outperform rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JesusIsKing1 Feb. 23 at 4:39 PM

$TNGX Added. Like the look of this one. Plenty of recent institutional buying, strong financials and looks strong.

0 · Reply

_EmproX Feb. 23 at 4:19 PM

$AUST $PNBK $TNGX $ODYS •<•

0 · Reply

notreload_ai Feb. 23 at 3:52 PM

0 · Reply

notreload_ai Feb. 23 at 3:09 PM

$AMPX $BOBS $LIFE $TNGX -- THE WSJ

0 · Reply

wheatbreadmetropolis Feb. 22 at 9:30 PM

$TNGX #1 trending.

0 · Reply

JesusIsKing1 Feb. 22 at 8:38 PM

$NOK Buying this and $TNGX tomorrow. Money to be made with this great companies in their infancy.

0 · Reply

JesusIsKing1 Feb. 22 at 8:37 PM

$TNGX Adding this one to my portfolio tomorrow along with $NOK.

0 · Reply

OfficialStocktwitsUser Feb. 16 at 8:28 PM

1 · Reply

BillionerOfKing Feb. 16 at 1:05 PM

0 · Reply

UgoGreg Feb. 15 at 5:18 PM

$TNGX https://youtu.be/nCPt9XhiRxk

0 · Reply

birdman1001 Feb. 13 at 9:22 PM

$TNGX This is a corp. set-up to create retirees, unfortunately they are very patient about when they want to get there.

0 · Reply

Chauncy_Peppertooth Feb. 13 at 4:10 PM

$TNGX still crickets in here too

0 · Reply

UgoGreg Feb. 7 at 10:34 PM

$TNGX https://youtu.be/b4CDDEB3OQo

0 · Reply

Chauncy_Peppertooth Feb. 6 at 11:19 PM

$TNGX wtf- Gug just went +50% on their price estimate on no news? Someone must have an early idea on data…maybe lung is imminent. New ceo seems like a rockstar…

1 · Reply

erevnon Feb. 6 at 3:13 PM

Guggenheim maintains Tango Therapeutics $TNGX at Buy and raises the price target from $12 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

VolumeX Feb. 4 at 1:44 PM

$TNGX is a clinical-stage biotech focused on immuno-oncology; its pipeline is early, and the stock is a pure speculation on preclinical and early clinical data.

1 · Reply

StockConsultant Feb. 4 at 1:05 PM

$TNGX Tango Therapeutics stock, strong day, watch for a bull flag breakout at https://stockconsultant.com/?TNGX

0 · Reply

BillionerOfKing Feb. 3 at 11:47 PM

$TNGX Current Stock Price: $12.57 Contracts to trade: $12.5 TNGX Feb 20 2026 Call Entry: $1.62 Exit: $2.03 ROI: 25% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Danielord Feb. 3 at 3:12 PM

$EDBL $GXAI $JBDI $LXEH $TNGX thank u gor $TNGX this is huge

0 · Reply

DaBullRunner Feb. 3 at 3:04 PM

$TNGX telling you I am giving you LIFE CHANGING tickets 🚨GCTS🚨is my next ASTS in the making👇💰💰💰 $JBDI $GXAI $EDBL $LXEH watching

0 · Reply

UgoGreg Jan. 31 at 5:16 PM

$TNGX https://youtu.be/tAh290QykVA

0 · Reply

Market Cap	1.64B
Revenue (ttm)	42.07M
Net Income (ttm)	-130.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-309.72%
Debt to Equity Ratio	0.00

Volume	4,610,235
Avg Vol	2,889,530
Day's Range	N/A - N/A
Shares Out	134.68M
Stochastic %K	12%
Beta	1.75
Analysts	Strong Sell
Price Target	$15.25